The city-based company had registered net profits at Rs 37.77 crore during corresponding period of previous year.
For the April-December 31, 2017 period, net profits of the company wentup to Rs 114.37 crore from Rs 104.34 crore registered during year ago period.
Total income for the October-December 2017 quarter surged to Rs 409.38 crore from Rs 345.34 crore registered during year ago period.
For the nine month period ending December 31, 2017 total income rose to Rs 1,136.86 crore, as against Rs 1,001.41 crore registered during year ago period.
"In response to the emerging growth possibilities we are delighted to announce a preferential allotment of Rs 250 crore to the promoters", he said in another press release.
The funds raised would be used to scale the business in "clinical and regulatory spaces" inorganically through strategic acquisitions in North American and European markets, he said.
Shares of the company ended at Rs 167 apiece upby 1.77 per cent over previous close in BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
